Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 5/20 | 0.60 |
| ▸ | NPY1R | P25929 | 3/20 | 0.54 |
| ▸ | NPY2R | P49146 | 3/20 | 0.54 |
| ▸ | NPY4R | P50391 | 3/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462005 | 0.98 | GHSR (0.58) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL29619338 | 0.96 | GHSR (0.60) | GHSR | |
| SCHEMBL29461985 | 0.94 | TUBB4A (0.58) | GHSR | |
| SCHEMBL29972999 | 0.93 | GHSR (0.62) | GHSR | |
| SCHEMBL29462003 | 0.92 | GHSR (0.54) | GHSRNPY1RNPY2RNPY4RERAP2 | |
| SCHEMBL30485843 | 0.92 | GHSR (0.57) | GHSRNPY1RNPY2RNPY4R | |
| SCHEMBL29808394 | 0.92 | GHSR (0.63) | GHSR | |
| SCHEMBL29748708 | 0.92 | GHSR (0.61) | GHSR | |
| SCHEMBL29666286 | 0.92 | GHSR (0.59) | GHSR | |
| SCHEMBL30797170 | 0.92 | OPRM1 (0.57) | ERAP2ERAP1LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | STEALTH BIOTHERAPEUTICS INC. (US) | 2023-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612633-B2 | Methods and compositions for preventing or treating ophthalmic conditions | CRYAA, CRYAB, IAPP | GHSR 619/4885NPY1R 144/4885NPY2R 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.